On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

GlaxoSmithKline's ViiV wins FDA nod for three-in-one HIV treatment

ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, picked up FDA approval for a single pill that combines three antivirals and promises to challenge a leading treatment from Gilead Sciences.

ViiV Healthcare receives FDA approval for Triumeq®

London, UK, 22 August, 2014 – ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg)...

Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration

Hamburg, Germany, and Branford, CT: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the start of a multi-year compound management agreement between Evotec (US)...

UCSF spinout launches crowdfunding campaign for Ebola drug

Startup OncoSynergy is jumping on the crowdfunding bandwagon to raise money to test a drug candidate in its pipeline against the deadly Ebola virus, which has infected 2,473 people and killed 1,350 of those in the worst outbreak of the disease in West Africa.

Pozen dials down its R&D efforts; Kindred tanks as dog drug comes up short;

@FierceBiotech: Low levels of enzyme in Alzheimer's brains suggest new drug target. More from FierceBiotech Research | Follow @FierceBiotech @JohnCFierce: ICYMI yesterday: J&J, AstraZeneca...

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

BOTHELL, Wash. and VANCOUVER, British Columbia -- OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small...

Sprout pockets $15M for its long-delayed 'female Viagra'

North Carolina's Sprout Pharmaceuticals put together a $15 million funding round, cash the biotech will use to make another go at FDA approval for its female sexual dysfunction treatment.

Pfizer-AstraZeneca sequel could hit theaters next week

Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.

Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer

Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer PORTLAND, Ore., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical...